SBIR is one of NCI’s engines of innovation for developing and commercialising novel technologies in prevention, diagnosis and treatment of cancer
PACT & Health, Branford, CT, US has been awarded Phase I Small Business Innovation Research (SBIR) by National Cancer Institute (NCI). The product I-ConradPET will provide therapy to certain cancers that are currently lacking precision treatment. By avoiding collateral damage to the normal tissue/organs improves the patient’s quality of life.
NCI, an institute of National Institute of Health (NIH) leads and supports cancer research across the US to advance scientific knowledge and help people to live longer and healthier. The SBIR is one of NCI’s engines of innovation for developing and commercialising novel technologies in prevention, diagnosis and treatment of cancer. In addition to funding, NCI contributes tremendously to mentoring and networking for small businesses with next-generation cancer technologies.
Dr Rao VL Papineni, CEO, PACT & Health, and Principal Investigator of the project describes that I-ConradPET’s strength relies on the technological innovations that include the fabrication of a novel nano-complex, and the use of a novel excitation X-ray source. Dr Papineni along with Dr Sunil Krishnan, Radiation Oncologist, Mayo Clinic and Dr Pulickel Ajayan, Materials Science and Nanoengineering Department, Rice University bring decades of experience and critical expertise to this combinatory cancer treatment.